An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: a case report

Frontiers in Oncology

Oncology

Yongye Huang¹  Dianhe Li²  Senmiao Huang²  Fuxi Huang²  Ying Tian³  Yating Zheng⁴  Xuefeng Zhong⁴  Mengli Huang⁴  Guojie Lu⁵ 

[1] Digestive Center Area Two, Guangzhou Panyu Central Hospital, Guangzhou, China;Oncology Department, Guangzhou Panyu Central Hospital, Guangzhou, China;Pathology Department, Guangzhou Panyu Central Hospital, Guangzhou, China;The Medical Department, 3D Medicines Inc., Shanghai, China;Thoracic Surgery, Guangzhou Panyu Central Hospital, Guangzhou, China;

关键词: intrahepatic cholangiocarcinoma (ICC);    EML4-ALK rearrangement;    ALK fusion;    ensartinib;    targeted therapy;   

DOI  :  10.3389/fonc.2023.1191646

 received in 2023-03-22, accepted in 2023-08-04,  发布年份 2023

来源: Frontiers

【 摘 要 】

Systemic chemotherapies are the primary treatment options for patients with unresectable and metastatic intrahepatic cholangiocarcinoma (ICC), but the effectiveness of current systemic therapies is limited. The development of targeted-therapy has changed the treatment landscape of ICC, and comprehensive genome sequencing of advanced cholangiocarcinoma patients could be beneficial to identify potential targets to guide individualized treatment. Herein, we reported an unresectable and metastatic ICC patient who detected EML4-ALK rearrangement in peripheral blood, which was later confirmed on tissue-based testing, and achieved partial response (PR) after first-line treatment with ensartinib. This case suggests that the liquid biopsy is of clinical value for unresectable or metastatic ICC, and the discovery of rare molecular targets provides new therapeutically approaches for advanced ICC patients.

【 授权许可】

Unknown   
Copyright © 2023 Huang, Li, Huang, Lu, Tian, Zhong, Zheng, Huang and Huang